Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2016
At a glance
- Drugs MVAME 03 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Panacela Labs
- 07 Jun 2017 Biomarkers information updated
- 11 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
- 11 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017.